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Abstract
Background: Inherited factors predisposing individuals to breast and ovarian cancer are largely unidentified in a majority of
families with hereditary breast and ovarian cancer (HBOC). We aimed to identify germline copy number variations (CNVs)
contributing to HBOC susceptibility in the Finnish population.
Methods: A cohort of 84 HBOC individuals (negative for BRCA1/2-founder mutations and pre-screened for the most
common breast cancer genes) and 36 healthy controls were analysed with a genome-wide SNP array. CNV-affecting genes
were further studied by Gene Ontology term enrichment, pathway analyses, and database searches to reveal genes with
potential for breast and ovarian cancer predisposition. CNVs that were considered to be important were validated and
genotyped in 20 additional HBOC individuals (6 CNVs) and in additional healthy controls (5 CNVs) by qPCR.
Results: An intronic deletion in the EPHA3 receptor tyrosine kinase was enriched in HBOC individuals (12 of 101, 11.9%)
compared with controls (27 of 432, 6.3%) (OR= 1.96; P= 0.055). EPHA3 was identified in several enriched molecular functions
including receptor activity. Both a novel intronic deletion in the CSMD1 tumor suppressor gene and a homozygous
intergenic deletion at 5q15 were identified in 1 of 101 (1.0%) HBOC individuals but were very rare (1 of 436, 0.2% and 1 of
899, 0.1%, respectively) in healthy controls suggesting that these variants confer disease susceptibility.
Conclusion: This study reveals new information regarding the germline CNVs that likely contribute to HBOC susceptibility in
Finland. This information may be used to facilitate the genetic counselling of HBOC individuals but the preliminary results
warrant additional studies of a larger study group.
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Introduction
Breast cancer (BC) is the most common cancer among women
in western countries, including Finland. Inherited BC risk is
known to be associated with rare, highly penetrant variants,
mainly single nucleotide polymorphisms (SNPs) and small
insertions and deletions (indels) in BRCA1 and BRCA2, which
account for nearly 20% of hereditary breast and/or ovarian
cancer (HBOC) cases in Finland [1–3]. Additionally, variants in
other BRCA1/2 interacting genes, including CHEK2, PALB2,
RAD51C, and Abraxas, are known to account for a low proportion
of HBOC susceptibility in the Finnish population [4–7].
In addition to SNPs and small indels, copy number variations
(CNVs) contribute to susceptibility to complex diseases and
disorders [8]. A CNV is a segment of DNA (1 kb or larger) that
presents an altered copy number compared with the reference
genome [9]. Depending on the location, CNVs may affect target
gene expression through a dosage effect or by disrupting gene
regulatory elements [10]. CNVs were initially associated with
neurological disorders, but studies have demonstrated the role of
CNVs also in other diseases, including several cancers [11–15].
Despite the fact that several heritable risk factors for breast and
ovarian cancer have been recognised, in the majority (up to 80%)
of HBOC families, inherited risk is likely explained by yet
unknown factors, which makes genetic counselling and clinical
surveillance challenging. The contribution of rare germline CNVs
to breast and ovarian cancer susceptibility has also been
established in the Finnish population, but their role is mostly
unexplored [16,17]. Therefore, new information regarding germ-
line CNVs and their role in HBOC predisposition is needed to
identify CNVs that may be used clinically to facilitate the genetic
counselling of HBOC families.
To determine additional genetic factors contributing to HBOC
susceptibility in the Finnish population and gain new information
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for genetic counselling, we analysed germline CNVs in a cohort of
84 well-characterised HBOC BRCA1/2-founder mutation-nega-
tive Finnish individuals who have been pre-screened for the most
common high- and moderate-penetrant genes [18].
Materials and Methods
Study Material
Index individuals from 84 HBOC families were collected from
the Tampere University Hospital Genetics Outpatient Clinic
between January 1997 and May 2008. Individuals were selected
according to previously reported high-risk hereditary BC criteria
[18]. All individuals had been determined to be founder mutation-
negative by minisequencing the 28 previously known Finnish
BRCA1/2 mutations and a protein truncation test (PTT) for
BRCA1 exon 11 and BRCA2 exons 10 and 11. Eighty-one of the
individuals included in this study have previously been charac-
terised and screened for germline alterations in seven known BC-
associated genes [18]. In addition, the index individuals from three
additional HBOC families were included (described in File S1).
For CNV validation analysis, index individuals from 20 additional
HBOC families, collected from Turku University Hospital
Genetics Outpatient Clinic between 2007 and 2011 were utilised.
Clinical characteristics of the 20 additional HBOC individuals
(negative for BRCA1/2-mutations) are described in File S2. As
controls, 905 DNA samples from anonymous healthy females,
collected from the Finnish Red Cross, were used. All of the HBOC
individuals studied have been informed of the analyses, and they
have given written consent to use their existing DNA samples.
Permission for the research project has been received from the
Ethical Committees of Tampere and Turku University Hospitals
and the National Authority for Medicolegal Affairs.
Copy Number Variation Analysis
The DNA samples from 84 HBOC individuals and 36 controls
were genotyped by using the genome-wide SNP array HumanCy-
toSNP-12 v.2.1 Beadchip (Illumina, Inc, San Diego, CA, USA),
which targets regions of known cytogenetic importance. Sample
preparation was performed according to the Infinium II assay
protocol (Illumina, Inc, San Diego, CA, USA) at the Institute for
Molecular Medicine, Finland. Log R Ratios (LRRs), B Allele
frequencies (BAF), and X and Y channel intensities for each
sample were exported from normalised Illumina data using
GenomeStudio software (GSGTv1.7.4) to perform CNV calling.
All of the samples had call rates greater than 99.5%. High sample
quality was ensured by applying previously reported quality
criteria [19]. Thus, 81 HBOC individuals and 35 controls were
suitable for analysis. CNV calling was performed with the
PennCNV (2009Aug27) program [19]. Additionally, two other
programs, QuantiSNP v2.3 [20] and cnvPartition v3.1.6 (Illumina
Inc, San Diego, CA, USA) were used to confirm the PennCNV
results when selecting CNVs for validation. Programs were used
with default parameters. CNVs spanning less than three SNPs
were filtered out.
Statistical Analyses
CNV distribution and median lengths were compared between
HBOC individuals and controls using the Wilcoxon test (R
v2.15.2, R Development Core Team, R Foundation for Statistical
Computing, Vienna, Austria). CNV carrier frequencies between
HBOC individuals and controls were compared with the Fisher’s
exact or x2 tests (R v2.15.2 and PLINK v.1.07 [21]). All P-values
were two-sided. A P-value,0.05 was considered statistically
significant. Furthermore, a VCD package was implemented in R
to estimate the numerical values of the odds ratios for enrichment
analysis in case a non-numerical value was returned from the
Fisher’s exact test [22].
CNV Validation and Genotyping by Quantitative Real-
time PCR (qPCR)
Selected CNVs were validated (6 CNVs) and genotyped in 20
additional HBOC individuals (6 CNVs) and in 299–869 additional
healthy female controls (5 CNVs) by TaqManH Copy Number
Assays and TaqManH real-time PCR, respectively, on an ABI
PRISM 7900 sequence detection system (Applied Biosystems,
Foster City, CA, USA). The following pre-designed TaqManH
Copy Number Assays were used: Hs04703682_cn (2q34),
Hs03458738_cn (3p11.1), Hs03253932_cn (5q15),
Hs06178677_cn (8p23.2), Hs02640223_cn (17q21.31), and
Hs04482315_cn (19q13.41). As an internal standard, a TaqManH
RNaseP Reference Assay (Applied Biosystems, Part Number
4403326) was run with the pre-designed TaqManH Copy Number
Assays in a duplex, real-time PCR reaction (see File S3 for more
details).
Data Analysis
Identified CNVs were queried for overlap with the Database of
Genomic Variants (DGV), Toronto (http://projects.tcag.ca/
variation/) using NCBI Genome Build 36 (hg 18). A CNV locus
was considered novel if it did not overlap with any of the
established CNV loci in the DGV. CNVs were annotated using
NCBI RefSeq genes (http://www.ncbi.nlm.nih.gov/RefSeq/) to
identify genes/exons overlapping the observed CNV loci. For
intergenic CNVs, the loci were expanded upstream and
downstream of the CNV to identify neighbouring genes.
Enrichment analyses, including Gene Ontology (GO) terms,
KEGG pathways, Pathway Commons, and Wikipathways, were
performed for CNV-affecting genes to reveal common functions of
the gene products using the Web-based Gene Set Analysis Toolkit
V2 (WebGestalt2) [23]. Furthermore, CNV-affected genes were
queried for overlap against genes listed in the NCBI Online
Mendelian Inheritance in Man (OMIM) database (http://www.
ncbi.nlm.nih.gov/omim) to identify genomic loci associated with
genetic disorders. In addition, a Genetic Association Database
(GAD) (http://geneticassociationdb.nih.gov/) search was per-
formed to identify genes analysed in previous association studies
for complex diseases and disorders.
Results
We performed genome-wide CNV analysis with a SNP array
targeting regions of known cytogenetic importance for individuals
from 84 Finnish HBOC families and 36 healthy controls. After
applying the quality control criteria, 81 HBOC individuals and 35
controls (n = 116) were included in the data analysis. The aim of
this study was to identify germline CNVs contributing to HBOC
susceptibility in Finnish families.
The PennCNV program was used to detect 545 autosomal
CNVs at 273 different genomic regions in HBOC individuals and
controls (n = 116). All of the identified CNVs are presented in
detail in Table S1. A summary of the CNVs identified by
PennCNV are shown in Table 1. The most important observa-
tions are that the average number of CNVs was slightly higher in
HBOC individuals compared with controls, and deletions were
more frequent in HBOC individuals. There was no statistically
significant difference in the median size the CNVs between the
HBOC individuals and controls (52.3 kb vs. 50.5 kb; P=0.90).
However, the median deletion size in HBOC individuals was
Copy Number Variations in Breast/Ovarian Cancer
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smaller compared with the controls (39.2 kb vs. 56.8 kb; P=0.07).
In contrast, the median duplication size was significantly larger
(P=0.01) in HBOC individuals compared with controls (68.7 kb
vs. 47.5 kb).
Annotation of all of the 545 CNVs against the genes in the
NCBI RefSeq database revealed 313 (57.4%) gene-affecting CNVs
(Table 1). Most importantly, gene-affecting deletions were more
common in HBOC individuals compared with controls (Table 1).
The identified CNVs were compared with healthy control sample
data collected in the Database of Genomic Variants. The main
observation was that the proportion of novel deletions to all
deletions in HBOC individuals was nearly three times larger
compared with controls (Table 1). In contrast, novel duplications
in HBOC individuals were observed less frequently compared with
controls (Table 1).
In this study, we focused on CNVs with the following
characteristics: they were enriched in HBOC individuals com-
pared with controls and 1) affected known or potential genes
contributing to HBOC predisposition (3 CNVs); or 2) they were
homozygous, and carriers presented with interesting clinical
outcomes (1 CNV); or 3) they were not reported in the Database
of Genomic Variants and affected genes related to BC (2 CNVs).
CNVs of interest were confirmed by another program (Quan-
tiSNP or cnvPartition). In total, six CNVs were selected for further
validation by qPCR, and they were genotyped in additional cohort
of index individuals from 20 HBOC families and five of the CNVs
were genotyped in 299–869 additional healthy female controls
(Table 2). The CNVs were correlated with clinical data from the
HBOC individuals (Table 3).
All six validated CNVs listed in Table 2 are located in genomic
regions related to BC. CNVs in the intronic regions of ERBB4 and
EPHA3 were enriched in HBOC individuals compared with
controls (Table 2). EPHA3 and ERBB4 encode proteins that are
involved in important signalling pathways. A homozygous deletion
in the 5q15 locus was identified in one BC patient (1 out of the
101, 1.0%) with drastic clinical characteristics (Tables 2 and 3).
This homozygous deletion was observed only in 1 out of the 899
(0.1%) healthy controls (Table 2). Deletions affecting the intronic
region of the CSMD1 tumor suppressor gene and exonic regions of
the highly penetrant BRCA1 were observed only in 1 out of the 101
(1.0%) HBOC individuals and CSMD1 deletion was identified in 1
out of the 436 (0.2%) controls (Table 2). Because large deletions in
BRCA1 are known to predispose to HBOC, there was no need to
screen for the deletion in additional controls. A duplication
affecting the coding region of the ERVV-2 gene, which belongs to
endogenous retroviruses, was more commonly homozygous in
HBOC individuals compared with controls (Table 2).
The clinical characteristics and family cancer history for
individuals with HBOC with the six validated CNVs are presented
in Table 3 (only CNVs identified in our original cohort of 81
HBOC individuals first analysed in the SNP array are presented).
Most importantly, 2 out of the 5 individuals with HBOC with a
novel deletion at the 2q34 ERBB4 locus had bilateral BC that was
diagnosed at #43 years of age (Table 3; families 221 and 212). We
were able to analyse the segregation of the 2q34 deletion in family
249 (Table 3) in which a deleterious BRCA1 variant was previously
identified in three individuals (Figure 1) [18]. The 2q34 deletion
was identified in the index’s mother (homozygous) and two
paternal cousins (heterozygous) (Figure 1). However, the index’s
daughter did not carry the deletion (Figure 1). A common feature
for all of the 3p11.1 deletion (at EPHA3 locus) carriers was ductal
BC diagnosed at #50 years and positive hormone receptor status
(6 out of the 8 carriers) in the cohort of 81 HBOC individuals
(Table 3). In the second cohort of 20 additional HBOC
individuals, 3p11.1 deletion was identified in two BC patients,
one ovarian cancer patient and a patient who had both breast and
ovarian cancer (File S2). Interestingly, all three patients with BC
presented ductal form of the cancer and estrogen and progesterone
receptor positive status (File S2). Intergenic deletion in the 5q15
region was of great interest because it was found as a homozygous
deletion in a BC patient who was diagnosed at age 29 years and
died of BC at the same age (Table 3, family 123). Additionally, one
heterozygous 5q15 deletion carrier had BC diagnosed at an early
age (24 years) and the other had thyroid and cervical cancers in
addition to BC diagnosed before age 40 years (Table 3; families
250 and 246). A novel deletion of high interest at 8p23.2, which
affects the CSMD1 intronic region, was identified in a patient with
ductal grade 2, hormone receptor positive BC diagnosed at a
relatively early age (36 years) with a paternal family history of BC
(Table 3, family 128 and Figure 2). A deletion affecting BRCA1,
Table 1. Summary of the identified copy number variations (CNVs) by PennCNV in 81 hereditary breast and/or ovarian cancer
(HBOC) individuals and 35 controls.
Average no
per sample Median size (kb) Gene-affecting (%) Novel CNVs (%)
All CNVs (n =545)
HBOC individuals 392/81 (4.8) 52.3 228/392 (0.58) 37/392 (0.09)
Controls 153/35 (4.4) 50.5 85/153 (0.56) 11/153 (0.07)
HBOC individuals only 215/81 (2.7) 52.5 141/215 (0.66) 36/215 (0.17)
Deletions (n =300)
HBOC individuals 222/81 (2.7) 39.2 109/222 (0.56) 30/222 (0.14)
Controls 78/35 (2.2) 56.8 34/78 (0.44) 4/78 (0.05)
HBOC individuals only 116/81 (1.4) 34.6 72/116 (0.62) 29/116 (0.25)
Duplications (n=245)
HBOC individuals 170/81 (2.1) 68.7 119/170 (0.70) 7/170 (0.04)
Controls 75/245 (2.1) 47.5 51/75 (0.68) 7/75 (0.09)
HBOC individuals only 99/245 (1.2) 60.8 69/99 (0.70) 7/99 (0.07)
Abbreviations: no =number.
doi:10.1371/journal.pone.0071802.t001
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NBR1, and NBR2 at 17q21.31 was identified in a patient with
hormone receptor-negative BC with a family history of ovarian
cancer (Table 3, family 252).
Enrichment analysis was performed for the CNV-affecting
genes to identify common functions of the gene products. EPHA3,
ERBB4 and BRCA1 were identified in several GO term categories
and pathways that were significantly overrepresented (P,0.05)
(presented in detail in Table S2). Both EPHA3 and ERBB4 were
identified to have molecular functions related to receptor activity,
transmembrane receptor activity, molecular transducer activity,
and signal transducer activity. In contrast, BRCA1 was identified in
several pathways related to DNA double-strand breaks and repair.
In addition, Online Mendelian Inheritance in Man (OMIM) and
The Genetic Association database searches revealed the role of
CSMD1 in BC.
Discussion
In this study, we aimed to identify CNVs contributing to HBOC
susceptibility in Finland and obtain new information for the
genetic counselling of HBOC families. We utilised a cohort of
well-characterised BRCA1/2-founder mutation-negative individu-
als from 84 Finnish hereditary breast and/or ovarian cancer
families who had been previously screened for variations in seven
known BC genes [18].
Here, we identified more gene-disrupting deletions in HBOC
individuals compared with controls suggesting that altered
function of their protein products, particularly in critical pathways,
could explain pathogenic events in HBOC individuals. Addition-
ally, a proportion of novel gene-affecting deletions, which were not
reported in healthy controls in the database, was higher in HBOC
individuals compared with controls, suggesting that these novel
CNVs are more likely to be disease -related.
We focused on CNVs that were enriched in HBOC individuals
compared with controls and affected genes that likely play a role in
HBOC predisposition. In addition, one intergenic deletion was
also included for further validation based on the homozygous form
of the aberration and notably poor clinical characteristics of the
carrier. Thus, six CNVs were considered to be the most relevant
for further validation. Because our sample number in the SNP
array was limited, we also genotyped the six CNVs in a cohort of
20 additional HBOC individuals. Furthermore, five of the CNVs
were genotyped in 299–869 additional healthy controls. Because
clinical characteristics of the additional cohort of 20 HBOC
individuals were comparable to our original cohort of 81 HBOC
individuals, we combined the observed frequencies of the CNVs in
both cohorts in Table 2. Additionally, we performed segregation
analysis of one family to determine how the CNV co-segregated
with the disease and another BC-associated variant. The CNVs
were compared with the clinical data of the HBOC individuals.
In this study, the most frequently observed aberration in HBOC
individuals was a deletion disrupting the EPHA3 intronic region
(Table 2). EPHA3 belongs to the ephrin receptor subfamily of the
receptor tyrosine kinase (RTK) family, which plays an important
role in normal cell physiology and disease pathogenesis [24].
Ephrin receptor signalling together with ephrin-ligands is known
to regulate both tumour growth and suppression in several
different cancers including BC [25]. According to recent studies,
altered EPHA3 expression is associated with gastric and colorectal
cancers, and CNVs in the EPHA3 region have been found to be
associated with haematologic malignancies [26–28]. However,
haematologic malignancies were not observed in EPHA3 deletion
carriers in this study. Our data suggest that an intronic deletion
may disrupt the EPHA3 regulatory elements, thus leading to
altered protein function and pathogenic BC events. Thus,
considering the important role of EPHA3 in signalling pathways,
the segregation of the intronic deletion should be studied in the
families and the deletion should be further screened in a larger
sample set.
The intergenic 5q15 deletion, particularly as a homozygous
deletion, is highly interesting from a clinical perspective. This
deletion was identified in a patient who had been diagnosed with
Table 2. Validated copy number variations.
Carrier frequency
Cytobanda Gene(s) Type Size (kb)b HBOC indc Controlsd P-values OR; 95%CI Statuse
2q34 ERBB4 intronic deletion 28.7–59.0 0.050 (5/101) 0.034 (12/358) 0.457 1.49; 0.52–4.28 Novel
3p11.1 EPHA3 intronic deletion 14.6 0.119 (12/101) 0.063 (27/432) 0.055 1.96; 0.97–3.94 Reported
5q15 – intergenic deletion 49.8 0.050 (5/101)f 0.063 (57/899) 0.845 0.92; 0.39–2.16 Reported
8p23.2 CSMD1 intronic deletion 10.8 0.010 (1/101) 0.002 (1/436) 0.259 4.33; 0.27–69.57 Novel
17q21.31 BRCA1, NBR1, NBR2 exonic deletion 99.0 0.010 (1/101) 0 (0/35) 0.555 na Reported
19q13.41 ERVV-2 exonic duplication 15.8–26.9 0.109 (11/101)g 0.102 (34/334) 0.322 1.37; 0.73–2.55 Reported
Abbreviations: CI = confidence interval; na = not available; OR = odds ratio.
aAccording to the NCBI Genome Build 36.1 (hg 18). Exact start and end positions of the CNVs are provided in Table S1.
bSize reported in HBOC individuals analysed in the SNP array (may vary between individuals).
cCombined frequencies of original cohort of 81 HBOC individuals (analysed in the SNP array) and cohort of 20 additional HBOC individuals (genotyped by TaqManH
Copy Number Assays). CNVs in the 2q34, 5q15, 8p23.2, and 17q21.31 regions were not observed in additional cohort of 20 HBOC individuals. Heterozygous deletion
(copy number 1) in the 3p11.1 region was also identified in 4 out of the 20 additional HBOC individuals (File S2). Heterozygous duplication (copy number 3) in the
19q13.41 region was also identified in 3 out of the 20 additional HBOC individuals (File S2). Homozygous duplication (copy number 4) in the 19q13.41 region was
identified in 1 out of the 20 additional HBOC individuals (File S2).
dThirty-five controls were first analyzed in the SNP array. CNVs were also screened in additional controls by TaqManH Copy Number Assays (excluding BRCA1 affecting
CNV since large deletions in BRCA1 coding regions are known to associate with breast and ovarian cancer susceptibility).
eSearch against the Database of Genomic Variants (DGV).
fDeletion in the 5q15 region was homozygous (copy number 0) in 1 out of the 101 (0.010) HBOC individuals and in 1 out of the 899 (0.001) controls and heterozygous
(copy number 1) in 4 out of the 101 (0.040) HBOC individuals and in 56 out of the 899 (0.062) controls.
gDuplication in the 19q13.41 region was homozygous (copy number 4) in 4 out of the 101 (0.040) HBOC individuals and in 3 out of the 334 (0.009) controls and
heterozygous (copy number 3) in 7 out of the 101 (0.069) HBOC individuals and in 31 out of the 334 (0.093) controls.
doi:10.1371/journal.pone.0071802.t002
Copy Number Variations in Breast/Ovarian Cancer
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e71802
BC at age 29 and died of the disease at the same age. Homozygous
deletion of the 5q15 locus was extremely rare in healthy controls (1
out of the 899, 0.1%) (Table 2), which emphasises the importance
of the variation. Moreover, it is possible that a fraction of the
anonymous controls may develop breast or ovarian cancer later in
life although they were healthy at the time of the blood draw. The
5q15 deletion may affect the transcriptional control of target gene
expression. Regulatory elements of the target gene can extend to
long distances outside of the transcription unit [29], which makes
gene expression regulation a complex process. Interestingly,
aberrant expression of the nearest neighbouring gene (1.0 Mb
distance), RGMB, has been implicated in BC [30]. Additional
analysis is needed to determine whether RGMB regulatory
elements exist in the 5q15 deletion locus. Moreover, a previous
copy number study of breast tumours-associated aberrations in the
5q15–5q21 locus with p53 status and patient survival suggests that
the 5q15 region may be important in BC predisposition [31].
Furthermore, to reveal possible functional elements located in the
deletion region, the Encyclopedia of DNA Elements (ENCODE)
(http://genome.ucsc.edu/ENCODE/) was utilised. Preliminary
analysis revealed enhancer and promotor-associated histone mark
(H3K4Me1) activity and DNase hypersensitivity, which indicate
that regulatory elements are active in this genomic region. Thus,
the 5q15 homozygous deletion requires special attention because it
may have clinical significance for screening families with BC with
early disease onset. Interestingly, two heterozygous 5q15 loss
carriers with lobular BC (Table 3, families 264 and 129) were
previously found to carry BC-associated CHEK2 variants [18].
The novel 8p23.2 deletion affects an intronic region in the
CSMD1 tumour suppressor gene. CSMD1 has mainly been
Table 3. The clinical characteristics and family cancer history for HBOC individuals analysed in the SNP array with the six validated
copy number variations.
Family Variation Cancer (age at dg)
Br/Ov Ca
histology/grade Receptor Status
Ca cases in the family
(age at dg if known)
221 2q34 del Bil. Br (39, 42) duct, gr 1 and ER+, PR+, HER22 and Br (51), Panc (54)
duct, gr 2 ER+, PR+, HER22
212 2q34 del Bil. Br (43) duct, gr na and na ER+, PR+, HER22 and na Br (52)
263 2q34 del Ov (69), Br (72) duct, gr 3 ER2, PR2, HER22 –
249 2q34 del Br (42) medullary, na na Br (35, 44, 57, 67, 71), Ute (39), Kid (67), Mel (63)
Ov (45), Skin, To (51), Co (78)
132 2q34 del Br (47) duct, gr 1 ER+, PR+, HER2 na Br (38)
232 3p11.1 del Br (34) duct, na ER+, PR+, HER2 na Br (39)
244 3p11.1 del Br (45) duct, gr 2 ER+, PR+, HER22 Bil. Br (,45), Br (,35, 46), Brain (67)
121 3p11.1 del Br (50) duct, gr 3 ER2, PR2, HER2+ 4xBr (36, 39, 40, 48)
207 3p11.1 del Br (38) duct, gr 3 na Bil.Br (64)
230 3p11.1 del Br (33), Kid (37) duct, gr 1 ER+, PR+, HER22 Br (70)
118 3p11.1 del Ov (32), Br (40), Mel (41) Mucinous and ER+, PR+, HER22 –
19q13.41 dup duct, gr 2
269 3p11.1 del Br (36) duct, gr 1 ER+, PR+, HER22 3xBr (52, 70, 72), Skin (66)
225 3p11.1 del Br (43) duct, gr 1 ER+, PR+, HER22 2xBr (52, 77), Kid (64)
123 5q15 del* Br (29) duct, gr 2 ER+, PR2, HER22 Br (65), Eso (73)
250 5q15 del Br (24) duct, gr 3 ER+, PR+, HER2+ Cer (30), Ov (83)
264 5q15 del Bil. Br (44) lob, gr 2 ER+, PR+, HER22 Br (44, 52)
19q13.41 dup
129 5q15 del BCC (70), Bil. Br (78), left: lob, gr 2, left: ER2, PR2, HER22, Bil. Br (59), BCC (48), Co (58)
Sto (82) right: duct, gr 1 right: ER+, PR+, HER22
246 5q15 del Thy (30), Cer (33), Br (39) duct, gr 3 ER2, PR2, HER2+ 2xBr (49, 54), Rectum (61)
128 8p23.2 del Br (36) duct, gr 2 ER+, PR+, HER22 2x Br (45, 58), GI (57), Mel (69)
252 17q21.31 del Br (46) duct, gr 3 ER2, PR2, HER22 Bil. Ov (46), Ov (44)
240 19q13.41 dup* Br (53) duct, gr 3 ER+, PR2, HER2+ 2xBr (42, 62)
206 19q13.41 dup Br (53) duct, gr 1 ER2, PR2, HER22 Bil. Br (64), Br (49)
133 19q13.41 dup Br (48) duct, gr 2 ER+, PR+, HER22 2xBr (73, 79), Int, BCC (60)
113 19q13.41 dup* Br (51), BCC (55) duct, gr 3 ER2, PR2, HER2+ Br (35)
239 19q13.41 dup* Br (37) duct, gr 2 ER+, PR+, HER22 Br (.90), Co
*Homozygous CNV.
Abbreviations: BCC = Basal-cell carsinoma; Bil. Br = bilateral breast; Br = breast; Ca = cancer; Cer = cervix in situ carsinoma/cervix carsinoma; Co= colon; Dg = diagnosis;
Del = deletion; Duct = ductal; Dup= duplication; Eso = esophagus; GI = gastrointestinal; gr = grade; Int = intestine; Kid = kidney; Lob = lobular; Mel =melanoma; na = not
available; Ov = ovary; Panc =pancreatic; Sto = stomach; Thy = thyroid; To = tongue; Ute = ute. Cancers diagnosed in the paternal side of the family are presented in italics.
Cancers diagnosed in siblings or their children of the index patients are underlined. Cancers diagnosed in the children of the index patients are presented in bold.
doi:10.1371/journal.pone.0071802.t003
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Figure 1. Family 249 pedigree. Index individual carries a novel 59.0 kb deletion in the 2q34 locus. The deletion affects intronic region of the
ERBB4 gene, which encodes a receptor tyrosine kinase family member that plays an important role in several cellular signalling pathways. The
deletion was also identified in index’s mother and two paternal cousins. Mother carried homozygous deletion (indicated with an asterisk). Index’s
daughter was tested to be negative for the deletion. Additionally, deleterious BRCA1 c.5095C.T variant has been previously identified in three
individuals in the family. Females are marked with circles and males are marked with squares. Index individual is marked with an arrow. Breast and
ovarian cancers are marked with black circles with the age at diagnosis. Other cancers are marked with grey and specified with the age at diagnosis
(Br: breast, Co: colon, Kid: kidney, Mel: melanoma, Ov: ovarian, To: tongue, Ute: uterus). Deceased individuals are marked with a slash. Current age of
index’s healthy sister is indicated. Generations are marked with the Roman numerals on the left. The pedigree figure has been modified from Kuusisto
et al, 2011 [18].
doi:10.1371/journal.pone.0071802.g001
Figure 2. Family 128 pedigree. Index individual carries a novel 10.8 kb deletion in the 8p23.2. The deletion affects intronic region of the CSMD1
tumor suppressor gene. Females are marked with circles and males are marked with squares. Number in circle or squares indicates descendants.
Index individual is marked with an arrow. Breast cancers are marked with black circles with the age at diagnosis. Other cancers are marked with grey
and specified with the age at diagnosis (Br: breast, GI: gastrointestinal, Mel: melanoma). Deceased individuals are marked with a slash. Current ages of
healthy females are presented in the paternal side of the family. In addition, the current age of index’s healthy daughter is indicated. Generations are
marked with the Roman numerals on the left.
doi:10.1371/journal.pone.0071802.g002
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associated with head and neck squamous cell carcinoma, but
CSMD1 losses is also reported to contribute to the tumourigenesis
of several other epithelial cancers, including BC [32]. In addition,
CSMD1 deletions and aberrant splicing have been shown to
contribute to altered CSMD1 function in vivo [32]. Moreover,
decreased CSMD1 expression has been associated with high
tumour grade and the poor survival of invasive ductal breast
carcinoma, and the role of CSMD1 expression as a potential BC
prognostic marker has been suggested [33]. In this study, the
CSMD1-affecting intronic deletion was identified in the index
individual for one BC family (1 out of the 101, 1.0%) (family 128,
Figure 2 and Table 3). In this family, the index patient and her
paternal aunt and grandmother had been diagnosed with BC at
ages 36, 45, and 58 years, respectively (Figure 2). In addition,
gastrointestinal cancer was diagnosed on the paternal side of the
family (father) (Figure 2). Interestingly, the CSMD1-affecting
deletion was observed only in 1 out of the 436 (0.2%) healthy
controls, suggesting that this rare variant likely predisposes
individuals to BC. We are currently seeking DNA samples from
the other family members (family 128) to determine whether the
variation co-segregates with BC in the family. In addition,
although the deletion should be screened for in larger sample
set, the CSMD1 gene is a potential candidate for the further study
of HBOC susceptibility in Finnish families.
A novel deletion at 2q34 affects the intronic region of the
ERBB4 gene, which is known to play a role in BC [34]. ERBB4
encodes an epidermal growth factor RTK subfamily member that
regulates several cellular processes and plays an important role in
cancer [35]. We found that the aberration in ERBB4 is 1.5 times
more common in HBOC individuals compared with controls
suggesting that it may be a disease-related low-risk variant
(Table 2). In addition, the clinical features of the ERBB4 deletion
carriers were interesting because two of the HBOC individuals
had bilateral BC diagnosed at a relatively early age (Table 3). To
further analyse the deletion, we were able to perform a segregation
analysis in one family in which a deleterious BRCA1 c.5095C.T
variant was previously recognised (Figure 1) [18]. Thus, three BC
cases in the family (index, index’s daughter and paternal cousin)
are explained by the paternally inherited high-penetrant BRCA1
variant. The ERBB4 deletion was observed on the maternal and
paternal sides of the family (Figure 1). However, in the mother,
who had BC diagnosed at an older age, the ERBB4 deletion was
homozygous, suggesting that the deletion could contribute to BC
development at an older age, particularly in its homozygous form.
Thus, it would be interesting to screen for the deletion in other BC
cases diagnosed at an older age on the mother’s side of the family
as well. Additionally, an ovarian cancer patient who was negative
for the highly -penetrant BRCA1 variant was found to carry a
heterozygous form of the 2q34 deletion, suggesting that the
deletion may also contribute to ovarian cancer risk to some extent
(Figure 1).
BRCA1 deletions are known to predispose to breast/ovarian
cancer [36]. In this study, a large deletion overlapping exons 1A-
13 of BRCA1 was observed in one individual with BC diagnosed at
age 46 years and with ovarian cancers diagnosed in her mother
and half-sister (Table 3, family 252). In our previous analysis, the
sample was excluded from the MLPA analysis due to a low sample
quality value [18]. The BRCA1 deletion encompassing exons 1A-
13 has been reported in a Finnish breast/ovarian cancer family
[37]. Here, the deletion was found to affect also the neighbouring
genes NBR1 (entire gene) and NBR2 (exons 1–10) according to the
PennCNV, QuantiSNP and cnvPartition programs. Similar
findings have been reported worldwide in a few studies [38,39].
Because the BRCA1 deletion is known to be clinically relevant,
MLPA analysis was performed to validate the BRCA1 deletion
(Figure S1). Genetic counselling was offered for the deletion carrier
patient.
The duplication identified at 19q13.41 affects exon 1 of the
ERVV-2 gene. ERVV-2 belongs to the human endogenous
retrovirus (ERV) family and the involvement of ERVs in the
pathogenesis of human cancer has been suggested but their roles in
biological disease processes are poorly understood [40]. Because
19q13 genomic region has been previously associated with BC
[41], this prompted us to further examine the duplication affecting
the ERVV-2 coding region. Screening for the duplication in
additional controls revealed that it was as common in controls
compared with HBOC individuals (Table 2). However, the
homozygous form of the variation was 4.4 times more common
in HBOC individuals compared with controls (Table 2), suggesting
that the aberration may contribute to breast and ovarian cancer
risk to some extent, but further studies are needed to confirm the
findings. Of interest, one of the homozygous duplication carriers
(Table 3, family 240) had been reported to carry a novel BRCA2
variant predicted to be pathogenic [18].
In conclusion, this study is a continuation of our previous work
with the aim of elucidating genetic factors contributing to HBOC
susceptibility in Finland. We have identified several potential
CNVs that likely increase the risk of HBOC susceptibility that may
thus explain a fraction of breast and ovarian cancer cases. The
aberrations at 3p11.1, 5q15, and 8p23.2 regions require special
attention because they may be utilised for the genetic counselling
of HBOC families, but more studies are needed to confirm the
preliminary findings.
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